Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This manuscript describes a simple method for the formulation and control of vaccines with a water-in-oil-in-water adjuvant at the laboratory scale, compatible with the safety requirements of live recombinant vaccines.

Abstract

Adjuvants play an important role to enhance the efficacy of vaccines and are often required to direct immune responses toward specific long-term protection. Several vaccination trials have described promising results with the combination of recombinant adenoviruses and water-in-oil-in-water (W/O/W) adjuvants. Specifically, the antibody response elicited by vaccines based on canine adenovirus type 2 (CAV2) vectors steadily increases after being formulated in a W/O/W emulsion. Thus, the production process directly impacts its physical properties, which are crucial to obtain stable, safe, and efficient vaccine emulsions. This article describes a lab-scale process for the formulation of O-206, a W/O/W adjuvant, in a total volume of 1 mL and 10 mL, that is compatible with safety requirements of live vaccines based on recombinant adenovirus. Moreover, this article provides reliable and simple quality control analyses of the W/O/W vaccine emulsion formulated with recombinant adenoviruses.

Introduction

In the context of growing populations, secure access to uncontaminated food while improving animal and human health will become increasingly important. The expression "One World, One Health" describes a multidisciplinary international cooperation associating animal and human health to notably better prevent and control zoonotic agents1. Indeed, 60% of emerging infectious diseases in humans are transmitted by animals2.

Nowadays, vaccination is still the most effective way to prevent and control infectious diseases in humans and animals. In comparison, only drinking water allows such a r....

Protocol

1. Emulsification process of 1 mL formulation for rodents

  1. Gently shake the vial of O-206 before opening and transfer 560 µL of O-206 into a 2 mL microtube using a positive displacement pipette.
  2. Add 440 µL of aqueous phase containing purified canine recombinant adenovirus (CAV2) at the desired concentration in a 2 mL microtube.
    CAUTION: CAV2 recombinant vectors are genetically modified organisms (GMOs) derived from canine adenovirus type 2, classified as a Risk Group II pathogenic mi.......

Representative Results

Typical results obtained from the appearance test are shown in Figure 1. An emulsion is stable if there is no default or non-critical defaults. A default is considered non-critical when the difference of both color and phase is low. Non-critical defaults are hand reversible because the properties of the emulsion are conserved (e.g., whitish phase at the surface). A default is considered critical when the physical properties of the emulsion are permanently altered: when there is a change in d.......

Discussion

The protocol in this study details two lab-scale processes adapted to the safety requirements of live vaccines based on recombinant adenoviruses formulated with W/O/W adjuvant.

These optimized protocols allow a robust and reproducible formulation. However, it is crucial to scrupulously respect certain critical steps. Firstly, it is important to obtain a final adjuvant/aqueous phase ratio of 50/50 weight/weight. Secondly, warming of the oil and aqueous phases before their assembly must ensure a.......

Acknowledgements

Manon Broutin was funded by a CIFRE PhD fellowship (2017/1080) from the French Association Nationale de la Recherche et de la Technologie (ANRT) in the framework of a public-private partnership between Ecole Nationale Vétérinaire d'Alfort and SEPPIC, part of Air Liquid Healthcare.

....

Materials

NameCompanyCatalog NumberComments
15 mL conical tubeFALCON352096
20 mL dispersing tubeIKA3700600Tube with rotor-stator element. Sterile model, with pierceable membrane
50 mL dispersing tubeIKA3701600Tube with rotor-stator element. Sterile model, with pierceable membrane
DMEM (1x) + GlutaMAX-IGIBCO61965-026
Fetal Calf SerumEUROBIOCVFSVF00-01
HomogenizerIKA3646000
Laser diffraction particle size analyzerMalvern PanalyticalMastersizer 3000
MDCK (NBL-2)ATCCCCL-34
Microtube 2 mLEPPENDORF30120094
O-201SEPPICMONTANIDE ISA 201 VG
O-206SEPPICMONTANIDE ISA 206 VG
Penicillin (10,000 U/mL) Streptomycin (10,000 µg/mL)GIBCO15140-212
Pipette Tips C POSD 1000 µL S 180/3RAININ17008609100 μL – 1000 μL
Positive-Displacement Pipette MR-1000RAININ17008580100 μL – 1000 μL
Sodium Chloride 0.9% injectableBBRAUN
Sodium pyruvate 100 mM (100x)GIBCO11360-039
Sterile glass vialWEST PHARMACEUTICAL SERVICES8072035Optional
Syringe 1 mLBBRAUN9166017VSyringe without rubber
Syringe 10 mLBBRAUN4606728VSyringe without rubber
Syringe 2 mLBBRAUN4606701VSyringe without rubber
Syringe 5 mLBBRAUN4606710VSyringe without rubber
Vial adapterWEST PHARMACEUTICAL SERVICES8072035Optional
Vortex mixerSCIENTIFIC INDUSTRIESSI-0256Vortex-Genie 2

References

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved